ukumab is an investigational human monoclonal IgG1 kappa antibody in Phase 3 development for the treatment of moderately to severely active rheumatoid arthritis (RA). It is not approved as a treatment for RA or any other indication anywhere in the world. Sirukumab targets the cytokine interleukin (IL)-6, a naturally occurring protein that is believed to play a role in autoimmune conditions like RA.
In December 2011, Janssen Biologics (Ireland) and GSK entered into a co-development and co-commercialisation license agreement with respect to sirukumab for RA. Prior to the agreement, Janssen Research & Development, LLC, had been developing sirukumab for RA.
About Rheumatoid Arthritis
Rheumatoid arthritis is a chronic, systemic inflammatory condition that is often characterized by symptoms that include pain, stiffness and inflammation, and in some cases, joint destruction and disability. It is estimated that 1.5 million Americans and more than 23.5 million people worldwide are affected by the condition, for which there is no cure.
About Janssen Biologics (Ireland) and Janssen Research & Development, LLC
At Janssen, we are dedicated to addressing and solving some of the most important unmet medical needs of our time in oncology, immunology, neuroscience, infectious diseases and vaccines, and cardiovascular and metabolic diseases. Driven by our commitment to patients, we bring innovative products, services and solutions to people throughout the world.
Janssen Biologics (Ireland) and Janssen Research & Development, LLC, are part of the Janssen Pharmaceutical Companies of Johnson & Johnson. Please visit http://www.janssenrnd.com/ for more information.
Page: 1 2 Related medicine technology :1
|SOURCE Janssen Research & Development, LLC|
Copyright©2012 PR Newswire.
All rights reserved
. Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin to Treat Patients with Type 2 Diabetes2
. Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism3
. WorkSmart MD Announces Expansion of its Synergy Billing Division to Help Community Health Centers4
. BiOptix Announces Fall 2012 Tradeshow and Symposia Schedule5
. Interventional Spine Announces its 75th Patient Treated with the PerX360 Percutaneous Spinal Fusion Technology6
. Precision Automation Expert DWFritz Automation Announces Website Launch www.DWFritz.com7
. CPhI South America Expands Offering for 2013, Announces Co-Location with Food Ingredients South America8
. EFJohnson Announces Impact Partner Dealer Program9
. Aethlon Medical Announces Renewal of DARPA Dialysis-Like Therapeutics Contract10
. Kallo Announces Purchase Order For Its Specialist EMR - EMCURx11
. CryoLife Announces Initiation of Quarterly Cash Dividend